Design of a pivotal phase III allergen immunotherapy study to assess the efficacy and safety of subcutaneously administered tyrosine adsorbed modified birch allergen + mpl

Design of a pivotal phase III allergen immunotherapy study to assess the efficacy and safety of subcutaneously administered tyrosine adsorbed modified birch allergen + mpl

Aberer W., Kuna P., Bjermer L., Pfaar O., Zielen S., Berger U., Lee D., Seybold M., Ernst A., Clausen A., Lis K., Wittmann A., Gunawardena K., Higenbottam T., Skinner M.A. EAACI, Munich, 2018